Oral APIs
Various
ApprovedCommercial
Key Facts
About ChemWerth
Established in 1982 by Peter Werth, ChemWerth is a family-owned, global leader in the generic API sector, offering end-to-end services from product development to commercial supply. The company leverages exclusive partnerships with over 30 manufacturing facilities across the U.S., Europe, India, and China, and boasts a track record of over 550 worldwide regulatory approvals. Its core value proposition is enabling customers to reach the market faster through integrated technical, analytical, and regulatory support, with a focus on complex molecules, oncologicals, and antibiotics.
View full company profileOther Various Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Programs | Richter Gedeon | Phase 3 |
| Oligonucleotide APIs | Bachem | Clinical/Commercial |
| Novel Plasma-derived Therapies | Tiantan Bio | Pre-clinical |
| Complex Injectable Generics Pipeline | Amphastar Pharmaceuticals | ANDA Filed / Development |
| Generic Portfolio | Strides Pharma | Approved |
| New Product Launches | FDC India | Development/Filing |
| Generic Products Portfolio | Celon Pharma | Approved/Commercial |
| New Generic Filings (e.g., for US/EU) | Bliss GVS Pharma | Regulatory Review |
| Pipeline of Complex Generics | Mayne Pharma Group | Development |
| Bag APIs | ChemWerth | Approved |